Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Andrey G. Sarafanov"'
Autor:
Andrey G. Sarafanov
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 10, p 8584 (2023)
Factor VIII (FVIII) is an important component of blood coagulation as its congenital deficiency results in life-threatening bleeding. Current prophylactic therapy of the disease (hemophilia A) is based on 3–4 intravenous infusions of therapeutic FV
Externí odkaz:
https://doaj.org/article/1eebf48dcd004244908f053f1bb4889c
Autor:
Svetlana A. Shestopal, Leonid A. Parunov, Philip Olivares, Haarin Chun, Mikhail V. Ovanesov, John R. Pettersson, Andrey G. Sarafanov
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 15, p 8134 (2022)
Single-chain variable fragments (scFv) are antigen-recognizing variable fragments of antibodies (FV) where both subunits (VL and VH) are connected via an artificial linker. One particular scFv, iKM33, directed against blood coagulation factor VIII (F
Externí odkaz:
https://doaj.org/article/026a20d758e149e5a1412c85d1c496da
Autor:
Haarin Chun, James H. Kurasawa, Philip Olivares, Ekaterina S. Marakasova, Svetlana A. Shestopal, Gabriela U. Hassink, Elena Karnaukhova, Mary Migliorini, Juliet O. Obi, Ally K. Smith, Patrick L. Wintrode, Prasannavenkatesh Durai, Keunwan Park, Daniel Deredge, Dudley K. Strickland, Andrey G. Sarafanov
Publikováno v:
Journal of Thrombosis and Haemostasis. 20:2255-2269
Deficiency in blood coagulation factor VIII (FVIII) results in life-threating bleeding (hemophilia A) treated by infusions of FVIII concentrates. To improve disease treatment, FVIII has been modified to increase its plasma half-life, which requires u
Characterization of protein unable to bind von Willebrand factor in recombinant factor VIII products
Autor:
Philip Olivares, John R Pettersson, Mikhail V Ovanesov, Stepan S Surov, Ekaterina S. Marakasova, Wells W. Wu, Rong-Fong Shen, Andrey G Sarafanov, Haarin Chun, Svetlana A Shestopal
Publikováno v:
Journal of thrombosis and haemostasis : JTHREFERENCES. 19(4)
Background Therapeutic products with coagulation factor VIII (FVIII) have a wide range of specific activities, implying presence of protein with altered structure. Previous studies showed that recombinant FVIII products (rFVIII) contain a fraction (F
Autor:
Mikhail V Ovanesov, John R Pettersson, Rong-Fong Shen, Timothy K Lee, Svetlana A Shestopal, Andrey G Sarafanov, Philip Olivares, Wells W. Wu, Haarin Chun, Stepan S Surov, Ekaterina S. Marakasova
Publikováno v:
Blood. 136:25-26
Introduction Therapeutic products with blood coagulation factor VIII (FVIII) have a wide range of protein contents per activity unit (or IU/mg, specific activity), available from previous studies (Lin et al, 2004; Butenas et al, 2009) and the prescri
Autor:
Svetlana A Shestopal, Andrey G Sarafanov, Ekaterina S. Marakasova, James H. Kurasawa, Haarin Chun, Elena Karnaukhova, Dudley K. Strickland, Nancy E. Hernandez, Philip Olivares, Gabriela U. Hassink
Publikováno v:
The Journal of Biological Chemistry
The low-density lipoprotein receptor (LDLR) family of receptors are cell-surface receptors that internalize numerous ligands and play crucial role in various processes, such as lipoprotein metabolism, hemostasis, fetal development, etc. Previously, r
Autor:
Jian-Jiang Hao, John H. McVey, Yideng Liang, James H. Kurasawa, Mikhail V Ovanesov, Elena Karnaukhova, Timothy K Lee, M. Lin, Andrey G Sarafanov, Svetlana A Shestopal
Publikováno v:
Journal of Thrombosis and Haemostasis. 15:709-720
Essentials Recombinant factor VIII (FVIII) is known to be expressed at a low level in cell culture. To increase expression, we used codon-optimization of a B-domain deleted FVIII (BDD-FVIII). This resulted in 7-fold increase of the expression level i
Autor:
Mikhail V Ovanesov, Svetlana A Shestopal, Leonid A. Parunov, Timothy K Lee, Andrey G Sarafanov
Publikováno v:
Blood. 132:1170-1170
Introduction Replacement therapy for Hemophilia A requires frequent infusions of Factor VIII (FVIII) due to its relatively short half-life of ~12 h in plasma. Previous attempts to extend this half-life by genetic and chemical modification of FVIII me
Mapping the Binding Region on the Low Density Lipoprotein Receptor for Blood Coagulation Factor VIII
Autor:
James H. Kurasawa, Svetlana A Shestopal, Andrey G Sarafanov, Elena Karnaukhova, Timothy K Lee, Evi Struble
Publikováno v:
Journal of Biological Chemistry. 288:22033-22041
Low density lipoprotein receptor (LDLR) was shown to mediate clearance of blood coagulation factor VIII (FVIII) from the circulation. To elucidate the mechanism of interaction of LDLR and FVIII, our objective was to identify the region of the recepto
Autor:
Andrey G Sarafanov, James H. Kurasawa, Svetlana A Shestopal, Timothy K Lee, Naveen Jha, Mikhail V Ovanesov
Publikováno v:
Protein Expression and Purification. 88:201-206
A recombinant single-chain variable antibody fragment (scFv) KM33 was previously described as a ligand that can inhibit the function of blood coagulation factor VIII (FVIII). This scFv was previously derived from an individual with anti-FVIII antibod